Throughout our history of operations, we’ve had the opportunity to execute a variety of exciting and complex projects for our Clients.
The nature of our business is based on high degree of trust and confidentiality, however we are always very excited to co-author or contribute to scientific publications which present our work and expertise.
- 2021 Preparation of heterocyclyl urea derivatives as modulators of tryptophan catabolism useful in treatment of diseases WO2019229464
- 2021 Preparation of substituted sulfonyl azacycles as modulators of hedgehog (Hh) signalling pathway WO2019043372
- 2021 Preparation of substituted cyclyl-sulfonamides as modulators of hedgehog (Hh) signalling pathway WO2019043373
Systemic lupus erythematosus (SLE) is a chronic and relapsing, autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. Mouse models of lupus are not only an indispensable tool for studying lupus immunopathogenesis but also serve as a powerful system for fast screening of new SLE treatments in order to evaluate their safety and efficacy prior to clinical trials. Due to the extensive heterogenicity of clinical manifestations of SLE in humans, each mouse model displays only specific attributes of the human lupus phenotype. The webinar gives an insight into the most commonly used mouse models of SLE, highlighting their similarities and differences and discussing the advantages of using one model over the other and tailoring it for specific needs in preclinical research in the context of our current understanding of the immunopathogenesis of SLE.
Dr. Anamarija Markota is an experienced scientist and a team leader in the In vivo pharmacology department at Fidelta focusing on immunobiology and in vivo modelling of inflammatory and autoimmune disorders. After obtaining a double MSc degree in Molecular Biotechnology and Bioindustrial Techniques and a PhD degree in Immunology, Dr. Markota conducted postdoctoral research in the field of immune-oncology and immunotherapy. She has three years of experience as a study director in preclinical research, mainly in the field of IBD and SLE.
Ardigen, a part of Selvita Group, organized a live webinar “AI methods in small molecule design”. The event took take place on Tuesday, June 15, 2021, at 04:00 PM CEST and was be held by experts from three companies from Selvita Group - Ardigen (Dr. Michał Warchoł and Dr. Krzysztof Rataj), Selvita (Dr. Tom Coulter), and Fidelta (Dr. Steve Price).
They presented and discussed various methods of AI application in drug design: the current state-of-the-art AI models for small molecules, which protein properties can be predicted, and how to generate new molecules for your project.